TLR10基因多态性与HBeAg阳性慢性乙型肝炎患者PEG-IFNα治疗临床转归的相关性分析  

Correlation analysis of TLR10 gene polymorphism and clinical regression of PEGIFNαtherapy in HBeAg-positive patients with chronic hepatitis B

作　　者：范敬静[1] 常彩芳[1] 陈宇[1] 韩永平[1] 刘金禄[2] 周小英 白雪 FAN Jing-jing;CHANG Cai-fang;CHEN Yu(Department of Infectious Diseases,The First Affiliated Hospital of Hebei North University(Zhangjiakou Hebei,075000)China)

机构地区：[1]河北北方学院附属第一医院感染内科,河北张家口075000 [2]河北北方学院附属第一医院微生物科

出　　处：《中西医结合肝病杂志》2023年第2期101-105,共5页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：河北省医学科学研究重点课题计划(No.20180827)。

摘　　要：目的:探讨分析TLR10基因多态性与HBeAg阳性慢性乙型肝炎(CHB)患者聚乙二醇化干扰素α(PEG-IFNα)治疗临床归转的相关性。方法:选取2019年8月至2020年8月收治的92例HBeAg阳性CHB患者,均予以PEG-IFNα进行治疗,6个月后根据HBeAg、HBeAb情况将患者分为应答组44例和非应答组48例。提取全血基因组DNA,测定TLR10基因多态性点位(RS10004195位点和RS11096957位点),分析其不同点位基因型和等位基因分布与乙型肝炎病毒感染的关系,进而探讨TLR10基因多态性与临床转归的相关性。结果:TLR10基因RS10004195位点基因型中,应答组AA+AT型基因分布频率为77.27%显著高于非应答组的52.08%,A等位基因频率65.91%显著高于非应答组的41.67%,差异有统计学意义(P<0.05);TLR10基因RS11096957位点基因型中,应答组AC+AA型基因分布频率为70.45%,与非应答组的62.50%差异无统计学意义(P>0.05),应答组A等位基因频率为61.36%显著高于非应答组的39.58%,差异有统计学意义(P<0.05);TLR10基因RS10004195位点中,A型基因、A等位基因频率和RS11096957位点中A等位基因频率是HBeAg阳性CHB患者PEG-IFNα治疗临床转归的独立危险因素(OR>1,P<0.05)。结论:TLR10基因RS10004195位点A型基因携带、A等位基因频率,RS11096957位点A等位基因频率是HBeAg阳性CHB患者PEG-IFNα治疗临床转归的独立危险因素,对CHB患者治疗应答反应具有较好评估作用,可为临床治疗提供指导依据。Objective:To investigate the correlation between TLR10 gene polymorphism and clinical regression of PEG-IFNαtherapy in HBeAg positive patients with chronic hepatitis B.Methods:A total of 92 HBeAg-positive chronic hepatitis B patients admitted to our hospital from August 2019 to August 2020 were selected and treated with PEG-IFNα.After 6 months of treatment,the patients were divided into response group(n=44)and non-response group(n=48)according to their treatment conditions.TLR10 gene polymorphic point sites(RS10004195 and RS11096957)were detected and the relationship between genotype and allele distribution of TLR10 gene and HBeAg infection was analyzed.Furthermore,the correlation between TLR10 gene polymorphism and clinical outcome was discussed.Results:In the Genotype of TLR10 gene RS10004195 locus,the distribution frequency of AA+AT gene in the response group was 77.27%,which was significantly higher than that in the non-response group(52.08%),and the A allele frequency was 65.91%,which was significantly higher than that in the non-response group(41.67%),with statistical significance(P<0.05).In the Genotype of TLR10 gene RS11096957 locus,the distribution frequency of AC+AA gene was 70.45%in the response group and 62.50%in the non-response group,which showed no statistical significance(P>0.05).The frequency of allele A in response group(61.36%)was significantly higher than that in non-response group(39.58%)(P<0.05).The frequency of type A gene and A allele at RS10004195 of TLR10 gene and the frequency of A allele at RS11096957 were independent risk factors for clinical outcome of PEG-IFNαtreatment in HBeA g-positive chronic hepatitis B patients(OR>1,P<0.05).Conclusion:TLR10 RS10004195 locus A gene carrier and A allele frequency,RS11096957 locus A allele frequency are independent risk factors for clinical regression of PEG-IFNαtherapy in hB eA g-positive patients with chronic hepatitis B,and have A good evaluation effect on patients’treatment response.It can provide guidance for clinical treatment.

关 键 词：Toll样受体10 基因多态性 HBEAG阳性 慢性乙型肝炎 PEG-IFNα治疗 临床转归 

分 类 号：R575.1[医药卫生—消化系统]